Nuklearmedizin 2022; 61(02): 148
DOI: 10.1055/s-0042-1745972
Abstracts | NuklearMedizin 2022
Leuchtturm
PET Onkologie

Translational imaging of the Fibroblast Activation Protein (FAP) using the new ligand Ga-68-OncoFAP-DOTAGA

P. Backhaus
1   Uniklinik Münster, Klinik für Nuklearmedizin, Münster
,
F. Gierse
2   Universität Münster, European Institute for Molecular Imaging (EIMI), Münster
,
M.C. Burg
3   Uniklinik Münster, Klinik für Radiologie, Münster
,
F. Büther
1   Uniklinik Münster, Klinik für Nuklearmedizin, Münster
,
I. Asmus
1   Uniklinik Münster, Klinik für Nuklearmedizin, Münster
,
J. Cufe
2   Universität Münster, European Institute for Molecular Imaging (EIMI), Münster
,
P. Dorten
2   Universität Münster, European Institute for Molecular Imaging (EIMI), Münster
,
D. Neri
4   ETH Zürich, Department of Chemistry and Applied Biosciences, Zürich, Schweiz
,
S. Cazzamalli
5   Philochem AG, Small Molecule Therapeutics, Otelfingen, Schweiz
,
K.P. Schäfers
2   Universität Münster, European Institute for Molecular Imaging (EIMI), Münster
,
S. Hermann
2   Universität Münster, European Institute for Molecular Imaging (EIMI), Münster
,
S. Wagner
1   Uniklinik Münster, Klinik für Nuklearmedizin, Münster
,
H.J. Breyholz
1   Uniklinik Münster, Klinik für Nuklearmedizin, Münster
,
M. Schäfers
1   Uniklinik Münster, Klinik für Nuklearmedizin, Münster
› Institutsangaben
 

Ziel/Aim The fibroblast activation protein (FAP) is an emerging target for molecular imaging and therapy in cancer[1]. OncoFAP is a novel small organic ligand for FAP with very high affinity[2]. In this translational study, we establish Ga-68-OncoFAP-DOTAGA (Ga-68-OncoFAP) radiolabeling, benchmark its properties in preclinical imaging and evaluate its application in clinical PET scanning.

Methodik/Methods Ga-68-OncoFAP was synthesized in a cassette-based fully automated labelling module. Lipophilicity, affinity, and serum stability of Ga-68-OncoFAP were assessed by determining logD7.4, IC50 values and radiochemical purity.Ga-68-OncoFAP tumor uptake and imaging properties were assessed in preclinical dynamic PET/MRI in murine subcutaneous tumor models. Finally, biodistribution and uptake in a variety of tumor types were analyzed in 12 patients based on individual clinical indications that received 163±50 MBq Ga-68-OncoFAP combined with PET/CT.

Ergebnisse/Results Ga-68-OncoFAP radiosynthesis was accomplished with high radiochemical yields. Affinity for FAP, lipophilicity and stability of Ga-68-OncoFAP measured are ideally suited for PET imaging. PET and gamma counting-based biodistribution demonstrated beneficial tracer kinetics and high uptake in murine FAP expressing tumor models with high tumor-to-blood ratios of 8.6±5.1 at 1 h and 38.1±33.1 at 3 h p.i. Clinical Ga-68-OncoFAP PET/CT and PET/MRI demonstrated favorable biodistribution and kinetics with high and reliable uptake in primary cancers (SUVmax 12.3±2.3), lymph nodes (SUVmax 9.7±8.3) and distant metastases (SUVmax up to 20.0).

Schlussfolgerungen/Conclusions Excellent preclinical and clinical imaging characteristics validate Ga-68-OncoFAP as a powerful alternative to currently available FAP tracers.



Publikationsverlauf

Artikel online veröffentlicht:
14. April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany